(Q38569940)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

New pharmacotherapy options for pulmonary arterial hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Marie-Camille Chaumais

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Xavier Jais

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Marc Humbert

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Olivier Sitbon

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

9

Gérald Simonneau

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

3

Caroline O'Connell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

4

David Amar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

Swanny Perrin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Laurent Savale

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

English

0 references

publication date

12 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

2113-2131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26290279%20AND%20SRC:MED&resulttype=core&format=json

Updated Clinical Classification of Pulmonary Hypertension

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Guidelines for the diagnosis and treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Updated treatment algorithm of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Bloodstream infections in patients given treatment with intravenous prostanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Pharmacokinetic evaluation of continuous intravenous epoprostenol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Prostacyclin in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Severe erythroderma as a complication of continuous epoprostenol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term outcome with intravenous iloprost in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Possible role of endothelin in endothelial regulation of vascular tone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Ambrisentan for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Drug treatment of pulmonary arterial hypertension: current and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Endothelin receptor blockade in the management of pulmonary arterial hypertension: selective and dual antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Targeted therapies in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Potential for pharmacokinetic interactions between ambrisentan and cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

The impact of drug-drug interactions on pulmonary arterial hypertension therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Nitric oxide and beyond: new insights and therapies for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Comparison of phosphodiesterase type 5 (PDE5) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

A new epoprostenol formulation for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its act

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Prostaglandin regulation of gastric slow waves and peristalsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Actions of prostanoids to induce emesis and defecation in the ferret.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

A stomach road or "Magenstrasse" for gastric emptying.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Macitentan and morbidity and mortality in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Regulation of nitric oxide-sensitive guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Riociguat for the treatment of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Riociguat for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Pulmonary arterial hypertension in patients treated by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177

Endothelin-1 in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1074177